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Abstract
Context: The KCNJ11 E23K variant is associated with type 2 diabetes mellitus (T2DM) in cross-sectional studies, but
conflicting findings have been reported from prospective studies.
Objective: This study aimed to evaluate whether the E23K variant could predict glycaemic progression in a Southern
Chinese population.
Methods/Principal Findings: We performed a long-term prospective study on 1912 subjects from the Hong Kong
Cardiovascular Risk Factors Prevalence Study (CRISPS). The KCNJ11 E23K variant was associated with the progression to
prediabetes after a median interval of 12 years on multinomial logistic regression analysis, even after adjustment for
traditional risk factors (OR 1.29, Page, sex, BMI and fasting plasma glucose [FPG] adjusted =0.02). Based on Cox proportional hazard
regression analysis, the E23K variant also predicted incident prediabetes (HR 1.18, Page, sex, BMI and FPG adjusted =0.021).
However, E23K was not associated with the progression to T2DM in either multinomial or Cox regression analysis, and
the association of E23K with glycaemic progression to either prediabetes or T2DM was significant only in unadjusted Cox
regression analysis (P=0.039). In a meta-analysis of eight prospective studies including our own, involving 15680
subjects, the E23K variant was associated with incident T2DM (fixed effect: OR 1.10, P=4610
23; random effect: OR 1.11,
P=0.035).
Conclusions: Our study has provided supporting evidence for the role of the E23K variant in glycaemic progression in
Chinese, with its effect being more evident in the early stage of T2DM, as the subjects progressed from normal glucose
tolerance to prediabetes.
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Introduction
Type 2 diabetes mellitus (T2DM) is a complex metabolic
disorder characterized by impaired insulin secretion and insulin
resistance. The pancreatic beta-cell adenosine triphosphate (ATP)-
sensitive potassium channel (KATP channel), regulates insulin
secretion through the coupling of glucose metabolism to
membrane electrical activity [1]. The KATP channel consists of
the inwardly-rectifying potassium channel pore-forming (Kir6.2)
subunits and the sulphonylurea receptor 1 (SUR1) subunits,
encoded by the inwardly-rectifying potassium channel subfamily J
member 11 (KCNJ11) gene and the ATP-binding cassette
subfamily C member 8 (ABCC8) gene, respectively. Based on its
potential function, KCNJ11 was identified as one of the T2DM
susceptibility genes through the candidate gene study approach
[2]. A non-synonymous variant at codon 23 of the KCNJ11 gene,
which causes a glutamic acid to lysine (E23K; rs5219) substitution
at the N-terminal, has been shown to be associated with T2DM
across various ethnic groups [3,4], including Chinese[5,6], in
cross-sectional studies. In vitro cell-based studies suggested that the
E23K polymorphism causes a reduction in the sensitivity of the
Kir6.2 subunit towards ATP, thereby leading to the inhibition of
insulin secretion [7]. The functional significance of the E23K
variant has also been confirmed in vivo, based on its association
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into consideration the insulin sensitivity of an individual [8]. More
recently, the association of the E23K variant and a different
KCNJ11 variant rs5215 [I337V; in strong linkage disequilibrium
(LD) with E23K] with T2DM have been confirmed in several
genome-wide association studies [9,10,11], generating renewed
interests in its potential role as a genetic marker for T2DM
development.
Conflicting results have been obtained, however, in prospective
studies on the association between the development of T2DM and
the E23K variant or its closely linked variant I337V. The
population-based Hisayama Japanese prospective study, which
considered only subjects with normal glucose tolerance (NGT) at
baseline, was the first to demonstrate that the E23K variant could
predict the development of T2DM [12]. Subsequently, the DESIR
Prospective Study reported significant association of this variant
with incident T2DM [13]. Moreover, the Nurses’ Health Study of
the United States (US) [14] and the EPIC-Potsdam prospective
study of Germany [8] also described the association of this variant
with T2DM development in female subjects. In contrast, two
earlier studies involving only subjects with impaired glucose
tolerance (IGT) at baseline from the US Diabetes Prevention
Program [15] and the Finnish Diabetes Prevention Study (DPS)
[16], the E23K polymorphism was not associated with T2DM
development [12]. A recent prospective study in Shanghai
Chinese, which examined the effect of the KCNJ11 I337V on
T2DM development, failed to demonstrate any association [17].
Given these divergent reports, it is important to further examine,
prospectively, the clinical relevance of the E23K variant on the
progression of glycaemia. The current study aimed to evaluate, in
a long-term prospective study, whether the E23K variant could
predict the progression of glycaemia in Southern Chinese.
Methods
Ethics statement
All participants were studied after written informed consent,
and the study protocol was approved by the Ethics Committee of
the University of Hong Kong.
Subjects
The Hong Kong Cardiovascular Risk Factors Prevalence Study
(CRISPS) is a population-based longitudinal study of cardiovas-
cular risk factors, in which unrelated Southern Chinese subjects
were recruited from the general population via random telephone
numbers in Hong Kong. Details of the CRISPS cohort were
previously described [18]. Briefly, in 1995–96 (baseline study),
2895 Hong Kong Chinese were invited to undergo a comprehen-
sive assessment of cardiovascular risks, including a 75 g oral
glucose tolerance test (OGTT). In 2000–2004, 1944 subjects
returned for follow-up study (CRISPS2) [19]. In 2005–2008, 1803
subjects participated in the latest 12-year follow-up study
(CRISPS3) (Figure 1). Subjects were classified as having NGT,
IGT, impaired fasting glucose (IFG) or T2DM according to the
World Health Organisation (WHO) 1998 diagnostic criteria [20].
Prediabetes was defined as having either IGT or IFG. Subjects
who were non-diabetic at baseline but had been receiving anti-
glycaemic drugs by CRISPS2 or CRISPS3 were classified as
T2DM at the respective follow-up. The inclusion criteria for
subjects involved in each analysis are as follow:
(i) Progression to prediabetes or T2DM by the end of
the 12-year follow-up. Progression to prediabetes:
subjects with NGT at baseline who had progressed to
IGT or IFG by CRISPS3 (12-year follow-up). Progression
Figure 1. Flow of CRISPS study subjects.
doi:10.1371/journal.pone.0028598.g001
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baseline who had developed T2DM by CRISPS3.
No progression: non-diabetic subjects (NGT/IGT/IFG) at
baseline whose glycaemic status remained unchanged by
CRISPS3 (i.e. persistent NGT/IGT/IFG).
(ii) Prediction of incident prediabetes. Incident predia-
betes: subjects with NGT at baseline who had developed
IGT or IFG by CRISPS2 or CRISPS3.
Persistent NGT: subjects with NGT at baseline who
remained NGT at subsequent follow-up visit(s).
(iii) Prediction of incident T2DM. Incident T2DM:
subjects who were non-diabetic (NGT/IGT/IFG) at
baseline and had converted to T2DM by CRISPS2 or
CRISPS3.
Non-diabetic: subjects who were non-diabetic (NGT/
IGT/IFG) at baseline and remained as non-diabetic at
subsequent follow-up visit(s).
(iv) Prediction of glycaemic progression. Glycaemic
progression: subjects with NGT at baseline who had
developed IGT, IFG or T2DM by CRISPS2 or CRISPS3;
and subjects who were IGT/IFG at baseline who had
converted to T2DM by CRISPS2 or CRISPS3.
Persistent NGT or persistent IGT/IFG: subjects who were
NGT or IGT/IFG at baseline whose glycaemic status
remained unchanged in subsequent follow-up visit(s).
Anthropometric and biochemical measurements
The anthropometric (including body mass index [BMI] and
waist circumference [WC]) and biochemical measurements
(including fasting plasma glucose [FPG], 2 hr post-OGTT glucose
[2 hrG] and fasting plasma insulin) were measured as previously
described [19]. The insulin resistance index based on the
homeostasis model assessment (HOMA-IR) was calculated as
(FPG [mmol/l] x fasting plasma insulin [mIU/l]/22.5) and
homeostasis model assessment of beta-cell function (HOMA-beta)
was calculated as (20 x fasting plasma insulin [mIU/l]/FPG
[mmol/l]-3.5) [21].
Genetic Analyses
The E23K variant was genotyped by the TaqMan Pre-designed
SNP Genotyping Assay (Assay ID:C__1594245_10; Applied
Biosystems, Foster City, CA, USA). Polymerase chain reactions
were performed in the GeneAmpHPCR System 9700 thermal
cycler according to the manufacturer’s protocols, and assay
products were analyzed using Applied Biosystems PRISMH 7000
Sequence Detection System for fluorescence intensity detection.
Hardy-Weinberg equilibrium (HWE) was examined by the
DeFinetti program (http://ihg2.helmholtz-muenchen.de/cgi-bin/
hw/hwa1.pl). The successful genotyping call rate was 100% and
concordance rate was 97.5%.
Meta-analysis and meta-regression analysis
We searched the PubMed database to identify relevant articles
related to the association of the KCNJ11 E23K or its closely linked
variant I337V with incident T2DM. We used the terms ‘‘KCNJ11’’
and ‘‘Type 2 diabetes’’ as key words to search for the related
articles. Publications were included in the current study if they
investigated, in a prospective design, the association of the E23K
or I337V variants with incident T2DM and provided sufficient
data (e.g. ethnicity, odds ratio [OR] and genotype counts) to allow
us to perform the analysis. For publications in which the crude OR
was not provided, OR under per-allele comparison was calculated
for analysis. Two publications [13,15] were excluded since the
available information was insufficient for us to calculate the ORs.
We used the Cochran’s x
2 test (Q-test) to examine the
heterogeneity between studies and a P-value of less than 0.05
was considered as significant. We also performed a meta-
regression analysis to evaluate whether particular covariates,
including the total sample size, ethnicity and follow-up time,
could explain the heterogeneity effects between different studies.
The meta-analysis was conducted by using the Comprehensive
meta-analysis version 2.0 software. The meta-regression analysis
was performed by SPSS (Version 16.0; Chicago, Illinois).
Statistical Analysis
All statistical analyses were performed with SPSS (Version 16.0;
Chicago, Illinois). Variables that did not follow a normal
distribution were natural-logarithmically-transformed before anal-
ysis. Multinomial logistic regression and Cox proportional hazards
regression (Cox regression) analyses were employed.
(i) Multinomial logistic regression. Multinomial logistic
regression was used to analyse the association of the E23K
variant in three categories of subjects simultaneously: (1)
progression to T2DM (NGT/IGT/IFG at baseline
-.T2DM by CRISPS3), (2) progression to prediabetes
(NGT at baseline -. IGT/IFG by CRISPS3) and (3)
persistent NGT or persistent IGT/IFG.
(ii) Cox regression. The Cox regression analyses (time-to-
event analyses) were also performed to evaluate the predictive
value of this variant with incident prediabetes, incident
T2DM and glycaemic progression. Subject’s glycaemic
statuses at all follow-up visit(s) (CRISPS2 and/or CRISPS3)
were considered.
Baseline variables that were significantly different (P,0.05)
between different groups or were biologically likely to affect
glycaemic status were included in the analyses with multiple
adjustments for confounding factors. Three models which involved
different sets of confounding factors were used in the multiple
adjustment analyses. Multiple adjustments were made for age, sex,
BMI and FPG in model 1; age, sex, BMI, FPG and 2 hrG in
model 2; and age, sex, BMI and HOMA-IR in model 3. All
associations were tested under the additive model. Power
calculations for the Cox regression analyses were performed using
the PASS 11 software. A two-tailed P-value of less than 0.05 was
considered as statistically significant.
Results
The current prospective study, included all subjects from the
CRISPS cohort who were non-diabetic at baseline and in whom
the E23K variant was successfully genotyped using stored DNA
samples (n=1912). The frequency of the risk (K) allele in the
CRISPS cohort (0.34) was comparable with those previously
reported in Chinese [5,6,17]. The genotype distribution of this
variant was in HWE in all analyses (all HWE P-values P .0.05,
ranging from 0.07 to 0.94).
Progression to prediabetes or T2DM by the end of the
12-year follow-up
Table 1 shows the baseline clinical characteristics of 209
subjects who had progressed to prediabetes (NGT at baseline -.
IGT/IFG by CRISPS3), 198 subjects who showed progression to
KCNJ11 E23K and Glycaemic Progression
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and 1185 subjects who showed no progression in glycaemic status
by the end of the 12-year study. Compared to those who showed
no progression, subjects who progressed to prediabetes or T2DM
consisted of more men (P=0.019), were older, had greater BMI,
WC, FPG and 2 hrG levels during OGTT, fasting insulin (all
p,0.001) and HOMA-IR (P=0.002). Differences in the level of
HOMA-beta, family history of diabetes and exercise (.30 minutes
per week) were not statistically significant (P.0.05).
In the multinomial logistic regression analysis, the E23K was
significantly associated with progression to prediabetes (unadjusted
P=0.011; OR[95%CI]:1.32[1.07–1.63]) but was not associated
with progression to T2DM (unadjusted P=0.961;
OR[95%CI]:1.01[0.81–1.26]) when compared to subjects who
showed no progression (Table 2). The possible association of the
E23K variant with progression to prediabetes was further analysed
with adjustments for different sets of confounding factors (Table 3).
In all three models, the E23K variant remained an independent
predictor for progression to prediabetes (Model 1: P=0.020,
OR[95%CI]:1.29[1.04–1.60]; Model 2: P=0.022, OR[95%CI]:
1.28[1.04–1.59]; and Model 3: P=0.016, OR[95%CI]:1.31[1.05–
1.62]). As previous studies have suggested that the E23K variant
might affect insulin secretion [7,8], association of the E23K variant
with an index for insulin secretion, HOMA-beta, was examined by
the linear regression analysis. However, the E23K variant showed
no significant association with HOMA-beta (P=0.573; be-
ta[95%CI]:0.01[20.03, 0.06]).
Prediction of incident prediabetes, incident T2DM or
glycaemic progression in the long-term prospective
study
We further examined the predictive value of the E23K variant
with incident prediabetes (NGT at baseline -. IGT/IFG by
CRISPS2 or CRISPS3) by using the Cox regression analysis. 412
incident prediabetes cases were compared with 1048 subjects with
persistent NGT when censored at the end of the study. The E23K
variant was significantly associated with incident prediabetes
(unadjusted P=2610
23, HR [95%CI]:1.25[1.09–1.44]) (Table 4).
With adjustment for age, sex, BMI and FPG, the E23K variant
remained as an independent predictor for incident prediabetes
(Adjusted P=0.021, HR[95%CI]:1.18[1.02–1.35]) and showed a
marginal association with incident prediabetes after adjustment for
age, sex, BMI and HOMA-IR (Adjusted P=0.051,
HR[95%CI]:1.15[1.00–1.33]) (Table 5). We also investigated the
Table 1. Baseline clinical characteristics of subjects who showed no progression, progression to prediabetes and progression to
T2DM at the end of 12-year.
Baseline Parameters No progression Progression to prediabetes Progression to T2DM Overall P-value
Number 1185 209 198 -
Sex (Male%) 44.8 52.2 53.5 0.019
Age (year) 42.6610.9 45.5611.2
** 48.7611.5
*** ,0.001
BMI (kg/m
2)2 3 . 4 63.3 24.763.4
*** 26.663.7
*** ,0.001
WC (cm) Male:80.768.3 Male:84.368.7
*** Male:88.268.4
*** ,0.001
Female:73.268.4 Female:76.668.5
** Female:81.969.5
*** ,0.001
FPG (mmol/l) 5.060.4 5.160.4 5.460.5
*** ,0.001
2 hrG (mmol/l) 5.961.5 6.161.1 7.761.8
*** ,0.001
Fasting insulin ( mU/ml)
a 4.5(3.0–6.8) 5.3(3.4–7.8)
* 6.6(4.4–10.5)
*** ,0.001
HOMA-IR
a 1.0(0.7–1.5) 1.2(0.8–1.8)
* 1.6(1.1–2.5)
*** 0.002
HOMA-beta
a 60.0(42.1–86.2) 63.7(42.2–91.9) 65.0(44.4–91.1) 0.393
T2DM family history(%) 17.1 19.7 20.4 0.404
Excercise (.30minutes per week) 43 44.5 38.4 0.399
Bonferroni Post Hoc test was applied for multiple comparisons. No progression as reference.
*P,0.05; ** P,0.01; *** P,0.001.
Data as mean6standard deviation or median with interquartile range.
a Natural-log-transformed before analysis. NGT: Normal glucose tolerance; IGT: Impaired glucose
tolerance; IFG: Impaired fasting glucose; BMI: Body mass index; WC: Waist circumference; FPG: Fasting plama glucose; 2 hrG: 2 hr post-OGTT glucose; HOMA-IR:
homeostasis model assessment index for insulin resistance; HOMA-beta: homeostasis model assessment index for beta-cell function.
doi:10.1371/journal.pone.0028598.t001
Table 2. Multinomial logistic regression analysis showing the association of the KCNJ11 E23K variant with progression to
prediabetes and progression to T2DM at the end of the 12-year study.
Genotype count
n KK EK EE HWE P-value EAF OR (95%CI) unadjusted P
Progression to T2DM 198 23 86 89 0.749 0.333 1.01 (0.81–1.26) 0.961
Progression to prediabetes 209 35 96 78 0.556 0.397 1.32 (1.07–1.63) 0.011
No progression 1185 137 513 535 0.407 0.332 1.00 (Ref) -
HWE: Hardy-Weinberg Equilibrium; EAF: Effect allele frequency; n: Number; OR: Odds ratio; CI: Confidence interval; P: P-value.
doi:10.1371/journal.pone.0028598.t002
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IGT/IFG at baseline -. T2DM by CRISPS2 or CRISPS3) by
comparing 226 incident T2DM cases with 1686 subjects who were
non-diabetic when censored at the end of the study. However, the
E23K variant did not show a significant association with incident
T2DM (unadjusted P=0.655, HR[95%CI]:0.96[0.79–1.16]).
Finally, the Cox regression analysis was performed for glycaemic
progression (NGT at baseline -. IGT/IFG/T2DM by CRISPS2
or CRISP3; and IGT/IFG at baseline -. T2DM by CRISP2 or
CRISPS3) which involved both incident prediabetes and incident
T2DM case subjects. A total of 638 subjects who showed
glycaemic progression were compared with 1274 subjects who
showed no progression in glycaemic status and the E23K variant
showed a significant association (unadjusted P=0.039,
HR[95%CI]:1.13[1.01–1.26]). However, the association with
glycaemic progression became insignificant after adjustment for
the confounding factors (P .0.05 in all 3 models).
Meta-analysis and meta-regression analysis
To comprehensively investigate the possible role of the E23K
variant in the prediction of T2DM, we conducted a meta-analysis by
combining our data with those from previous publications. We
combined our data with seven previous publications which examined
the E23K [8,12,14,16,22,23] or the strongly linked I337V variant
[17] in aprospectivedesign. The associationof the E23K variant with
T2DM incidence was investigated in a total of 2425 incident T2DM
cases and 13255 controls. A significant association was observed
between the E23K variant and incident T2DM (Fixed effect:
P=4 610
23; OR(95%CI):[1.10(1.03–1.18)]; Random effect:
P=0.035; OR(95%CI):[1.11(1.01–1.23)]). Figure 2 shows the forest
plot of the association between the E23K variant and incident
T2DM. There was subtle evidence of heterogeneity between studies,
although the Q-test was statistically insignificant (P=0.087). By using
meta-regression analysis, we found that the follow-up time
(P=8610
24)a n dt o t a ls a m p l es i z e( P=4 610
23) were the covariates
that could explain the heterogeneity between studies.
Discussion
In the current study, the KCNJ11 E23K variant was shown to be
associated with glycaemic progression, in the development of
prediabetes from NGT. However, we failed to demonstrate the
significant association of this variant with T2DM incidence. While
previous studies of the E23K variant in Chinese have focused
mostly on cross-sectional analyses [5,6], our well-established
CRISPS cohort, with 12-year prospective data, has allowed us
to study the contribution of this genetic variant to glycaemic
progression in a prospective setting. Case-control studies are useful
for the initial screening for susceptibility variants. On the other
hand, prospective studies are more helpful for substantiating the
clinical relevance of the identified variants.
Our data from the multinomial logistic regression showed that
the E23K variant was significantly associated with the progression
to prediabetes but not with the progression to T2DM at the end of
12-year study. Results from the Cox regression models also
showed that E23K could predict incident prediabetes but could
not predict incident T2DM. These findings would support the
hypothesis previously raised by Florez et al. that the E23K
polymorphism may exert its effect early in the course of T2DM,
from NGT to prediabetes, rather than influencing the progression
from prediabetes to T2DM. They were unable to show the
significant association of the E23K variant with T2DM develop-
ment in a large prospective study which involved 3534 subjects
who had IGT at baseline [15]. In fact, previous studies have
demonstrated the presence of impaired insulin secretion in the
early stage of T2DM [24].
On the other hand, our observation that the E23K variant only
showed a significant association with the development of
prediabetes but not with that of T2DM could have been due to
a lack of power in the current study. With the modest effect size of
the E23K variant, we have insufficient power to detect a
significant association with T2DM with our relatively small
sample size and limited number of incident cases. Based on the
Table 3. Multiple multinomial logistic regression showing the association of the KCNJ11 E23K variant with progression to
prediabetes and progression to T2DM, adjusted for confounding factors.
Model 1
a Model 2
b Model 3
c
OR (95%CI) Adjusted P OR (95%CI) Adjusted P OR (95%CI) Adjusted P
Progression to T2DM 1.01 (0.79–1.28) 0.958 0.94 (0.72–1.21) 0.613 1.00 (0.78–1.27) 0.981
Progression to prediabetes 1.29 (1.04–1.60) 0.020 1.28 (1.04–1.59) 0.022 1.31 (1.05–1.62) 0.016
No progression 1.00 (Ref) - 1.00 (Ref) - 1.00 (Ref) -
aModel 1: Multiple adjustments made for age, sex, BMI and fasting glucose.
bModel 2: Multiple adjustments made for age, sex, BMI, fasting glucose and 2-hr glucose.
cModel 3: Multiple adjustments made for age, sex, BMI and HOMA-IR.
OR: Odds ratio; CI: Confidence interval; P: P-value; Ref: Reference.
doi:10.1371/journal.pone.0028598.t003
Table 4. Cox regression analysis showing the association the KCNJ11 E23K variant with incident prediabetes.
Genotype count
n KK EK EE HWE P-value EAF HR (95%CI) unadjusted P
Incident prediabetes 412 69 177 166 0.067 0.382 1.25 (1.09–1.44) 2610
23
Persistent NGT 1048 106 453 489 0.942 0.317 1.00(Ref) -
HWE: Hardy-Weinberg Equilibrium; EAF: Effect allele frequency; n: Number; HR: Hazards ratio; CI: Confidence interval; P: P-value; Ref: Reference.
doi:10.1371/journal.pone.0028598.t004
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our power of study to detect a significant association (P,0.05) of
the E23K variant with incident prediabetes by the Cox regression
analysis was 85.8%, while the power for detecting a significant
association with incident T2DM was only 58.1%, even when the
same HR was applied in the calculation.
Given the discrepancies in prospective studies regarding the
association of the E23K variant with incident T2DM, we tried to
resolve this problem by conducting a meta-analysis of reported
prospective studies. In the current meta-analysis which involved a
total of 15680 subjects across different ethnic groups including our
own, we did observe a significant association of the E23K variant
with incident T2DM. This has clearly demonstrated that a large
sample size is crucial for detecting a genetic variant with modest
effect size. One limitation of the current meta-analysis was the
difference in diagnostic criteria for T2DM in different studies
Table 5. Multiple Cox regression analyses showing factors independently associated with incident prediabetes.
Incident prediabetes
Risk factors Model 1
b Model 2
c Model 3
d
HR (95%CI) Adjusted P HR (95%CI) Adjusted P HR (95%CI) Adjusted P
E23K (KK) 1.18 (1.02–1.35) 0.021 1.15 (1.00–1.32) 0.048 1.15 (1.00–1.33) 0.051
Age (years) 1.03 (1.03–1.04) ,0.001 1.03 (1.02–1.04) ,0.001 1.04 (1.03–1.05) ,0.001
Sex (Male) 1.15 (0.95–1.40) 0.157 1.01 (0.83–1.23) 0.922 1.03 (0.84–1.25) 0.793
BMI (kg/m
2) 1.07 (1.04–1.10) ,0.001 1.05 (1.02–1.08) 0.001 1.07 (1.04–1.10) ,0.001
FPG (mmol/l) 1.95 (1.51–2.53) ,0.001 1.65 (1.26–2.16) ,0.001 - -
2 hrG (mmol/l) - - 1.51 (1.37–1.67) ,0.001 - -
HOMA-IR
a - - - - 1.22 (1.02–1.45) 0.029
aNatural-log-transformed before analysis.
bModel 1: Multiple adjustments made for age, sex, BMI and fasting glucose.
cModel 2: Multiple adjustments made for age, sex, BMI, fasting glucose and 2-hr glucose.
dModel 3: Multiple adjustments made for age, sex, BMI and HOMA-IR.
BMI: Body mass index; FPG: Fasting plama glucose; 2 hrG: 2 hr post-OGTT glucose; HOMA-IR: homeostasis model assessment index for insulin resistance; HR: Hazard
ratio; CI: Confidence interval; P: P-value.
doi:10.1371/journal.pone.0028598.t005
Figure 2. Forest Plot. Meta-analysis of eight prospective studies on the association of KCNJ11 E23K variant with incident T2DM. The shaded
diamonds represent the individual OR of each study. The size of these shaded diamonds were proportional to the study weighting in the meta-
analysis. The un-shaded diamonds indicate the combined ORs calculated under the fixed and random effect models. The 95% confidence intervals
are demonstrated by the horizontal lines.
doi:10.1371/journal.pone.0028598.g002
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However, due to the limited number of available prospective
studies on the E23K variant, we were unable to perform subgroup
analyses.
Functional studies have suggested that the E23K variant may
affect insulin secretion [7,8]. Examining the indices of insulin
secretion would help to elucidate the possible effect of KCNJ11 on
insulin secretion. However, we were unable to detect any
significant association of the E23K variant with HOMA-beta. In
fact, previous studies also failed to show the association of this
variant with HOMA-beta [4,5,25,26]. Being a simple way to
estimate insulin secretion, HOMA-beta may not be the best index
of insulin secretion since its derivation relies solely on the basal
glucose and insulin levels. Other ways of estimating insulin
secretion that provide more optimal assessments of beta-cell
function, for example, the acute insulin responses during oral or
intravenous glucose tolerance test, or the disposition index would
be preferred. Unfortunately, the limited data available in our study
did not allow us to carry out such analyses.
In conclusion, we had demonstrated that the KCNJ11 E23K
variant independently increased the risk of developing prediabetes
in this prospective study, supporting its role in glycaemic
progression in Southern Chinese, with the effect being more
evident at the stage when NGT subjects progressed to prediabetes.
We were unable to demonstrate a significant association of this
genetic variant with T2DM, likely due to our relatively small
sample size. In the meta-analysis in which our data were combined
with those from seven other reported prospective studies, the
E23K variant was indeed shown to be predictive of T2DM.
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